Bioorthogonal pretargeting with tetrazine-functionalized lipid microbubbles (Tetra-MBs) captured by trans-cyclooctene (TCO)-modified anti-CD62p antibodies enables rapid, real-time ultrasound molecular imaging of acute thrombi in rats, but the platform has never undergone systematic translational evaluation. The open problem is to establish, in vivo, the pharmacokinetics and pharmacodynamics of the two-step pretargeting regimen (circulation half-life, biodistribution, clearance routes, dose-response), the safety and immunogenicity of repeated exposure to the TCO/tetrazine-modified reagents, and how far the approach generalizes across thrombus types, vascular beds, and hemodynamic conditions — the evidence base required before clinical application to acute thrombosis.

Background

Contrast-enhanced ultrasound uses gas-filled microbubbles (MBs, micron-scale lipid- or protein-shelled spheres) as intravascular contrast agents: their shells can carry targeting ligands so that MBs adhere to disease-associated molecular markers on the vessel wall, a technique called ultrasound molecular imaging. Conjugating ligands (typically antibodies) directly onto MB shells is hampered by slow binding kinetics, weak retention of MBs on targets under physiological blood flow and shear stress, and chemical damage to the fragile bubbles during coupling. Bioorthogonal 'click' chemistry offers an alternative: the inverse-electron-demand Diels-Alder reaction between a 1,2,4,5-tetrazine and trans-cyclooctene (TCO) is exceptionally fast, selective, and covalent, and proceeds in living systems without interfering with native biomolecules. In a two-step pretargeting scheme, a TCO-modified antibody is injected first to label the molecular target in situ; a tetrazine-bearing probe injected afterwards is then captured covalently at the target within seconds to minutes. For acute thrombosis the relevant target is CD62p (P-selectin), a cell-adhesion molecule that is stored in platelet granules and becomes exposed on the surface of activated platelets — at roughly 10,000 copies per activated platelet — during clot formation, making freshly formed thrombi densely decorated with this marker. Tetrazine-microbubble targeting was first demonstrated for non-thrombus targets (Zlitni et al., Angew. Chem. 2014; PLoS One 2017 for prostate-specific membrane antigen). Wang et al. (ChemBioChem 18(14):1364-1368, 2017) then combined tetrazine-functionalized phospholipid-shelled MBs (Tetra-MBs, diameter peak about 1.76 micrometers) with TCO-modified anti-CD62p antibody: in a parallel-plate flow chamber at a wall shear rate of 300 s−1^{-1}, pretargeted platelet aggregates captured roughly 17% of incident Tetra-MBs and produced durable echogenic contrast; in rats with ferric-chloride-induced inferior vena cava thrombosis (a standard chemical-injury model in which applying ferric chloride to the vessel exterior damages the vessel wall and triggers platelet-rich clot formation), intravenous TCO-antiCD62p followed by Tetra-MBs yielded rapid, selective, real-time thrombus contrast over a 2-hour monitoring window, with hematoxylin-eosin sections showing microbubble-like structures within the clots. This established the first bioorthogonal pretargeting route to activated-platelet-specific thrombus ultrasound imaging. The demonstration was, however, deliberately confined to a single venous thrombosis model in one vascular bed at one dose scale (about 1x10^5 MBs per injection), without quantified clearance, biodistribution, or dose-response measurements, without any repeated-exposure safety or immunogenicity testing, and without examination of other thrombus types (arterial versus venous, fresh versus aged) or hemodynamic regimes. An independent 2021 review of microbubble-based thrombus targeting (Wang Z. et al., Front. Bioeng. Biotechnol. 9:699450) states of exactly this construct that 'additional studies including pharmacokinetics and pharmacodynamics of the targeted moieties are required' and that 'the biosafety, accessibility, and cost of such constructs should also be considered'; the original group's own 2025 review of thrombus-directed micro/nano materials (Lu et al., Research 8:0614) still lists biosafety, standardized preparation, and site- and stage-dependent thrombus heterogeneity as open issues limiting clinical translation.

Problem Statement

For the two-step bioorthogonal pretargeting platform of Wang et al. (2017) — intravenous TCO-modified anti-CD62p antibody followed by tetrazine-functionalized microbubbles (Tetra-MBs) for activated-platelet-specific ultrasound molecular imaging of acute thrombi — establish the preclinical translational evidence base on all three of the following axes, each of which is required: (1) the in vivo pharmacokinetics and pharmacodynamics of the pretargeting regimen, including circulation half-life of Tetra-MBs and of the TCO-antiCD62p conjugate, biodistribution, clearance routes, and dose-response relationships of the imaging signal; (2) the safety profile of the reagents, including off-target interactions and the immunogenicity (or absence thereof) of repeated exposure to TCO- and tetrazine-modified agents; and (3) representative coverage of the approach beyond the single ferric-chloride rat inferior-vena-cava model originally used — at minimum two new thrombus preparations, demonstrated by distinct animals, namely one arterial thrombus model in a vascular bed other than the inferior vena cava and one thrombus aged at least 24 hours (non-acute), where a single preparation may satisfy several of the coverage conditions at once (the arterial model in a different bed also supplies the second vascular bed and the differing hemodynamic/shear regime); this representative panel resolves the axis, and an exhaustive sweep across all thrombus types, vascular beds, and shear conditions is not required. Taken together, these three axes constitute the preclinical translational evidence base that the source work left open and that must be established before clinical application of bioorthogonal pretargeted microbubble capture to the diagnosis of acute thrombosis.

References

  1. Wang T., Yuan C., Dai B., Liu Y., Li M., Feng Z., Jiang Q., Xu Z., Zhao N., Gu N., Yang F. (2017). Click-Chemistry-Mediated Rapid Microbubble Capture for Acute Thrombus Ultrasound Molecular Imaging. ChemBioChem 18(14):1364-1368. DOI: 10.1002/cbic.201700068. https://doi.org/10.1002/cbic.201700068
  2. Zlitni A., Janzen N., Foster F. S., Valliant J. F. (2014). Catching bubbles: targeting ultrasound microbubbles using bioorthogonal inverse-electron-demand Diels-Alder reactions. Angewandte Chemie International Edition 53(25):6459-6463. DOI: 10.1002/anie.201402473. https://doi.org/10.1002/anie.201402473
  3. Zlitni A., Yin M., Janzen N., Chatterjee S., Lisok A., Gabrielson K. L., Nimmagadda S., Pomper M. G., Foster F. S., Valliant J. F. (2017). Development of prostate specific membrane antigen targeted ultrasound microbubbles using bioorthogonal chemistry. PLoS ONE 12(5):e0176958. DOI: 10.1371/journal.pone.0176958. https://doi.org/10.1371/journal.pone.0176958
  4. Wang Z., Huang H., Chen Y., Zheng Y. (2021). Current Strategies for Microbubble-Based Thrombus Targeting: Activation-Specific Epitopes and Small Molecular Ligands. Frontiers in Bioengineering and Biotechnology 9:699450. DOI: 10.3389/fbioe.2021.699450. https://doi.org/10.3389/fbioe.2021.699450
  5. Lu C., Li C., Gu N., Yang F. (2025). Emerging Elastic Micro-Nano Materials for Diagnosis and Treatment of Thrombosis. Research 8:0614. DOI: 10.34133/research.0614. https://doi.org/10.34133/research.0614
  6. Tang J., Xu H., Li M., Liu Y., Yang F. (2024). Controllable Thrombolysis Using a Nanobubble-Imaging-Guided rtPA Targeted Delivery Strategy. BME Frontiers 5:0040. DOI: 10.34133/bmef.0040. https://doi.org/10.34133/bmef.0040
  7. Goncin U., Bernhard W., Curiel L., Geyer C. R., Machtaler S. (2022). Rapid Copper-free Click Conjugation to Lipid-Shelled Microbubbles for Ultrasound Molecular Imaging of Murine Bowel Inflammation. Bioconjugate Chemistry 33(5):848-857. DOI: 10.1021/acs.bioconjchem.2c00104. https://doi.org/10.1021/acs.bioconjchem.2c00104
  8. Liu X., Gong P., Song P., Xie F., Miller A. L. II, Chen S., Lu L. (2018). Fast functionalization of ultrasound microbubbles using strain promoted click chemistry. Biomaterials Science 6(3):623-632. DOI: 10.1039/c8bm00004b. https://doi.org/10.1039/c8bm00004b
  9. Zhang X., Lu Y., Wu X., Zhu W., Li R., Shan Q., Jiang S., Xia X., Ying B., Shen M., Xu Z., Wang S., Zhang K., Chen J. (2026). Strain-promoted click chemistry boosts microbubbles for targeted ultrasound imaging and cancer chemotherapy. Acta Biomaterialia 218:510-524. DOI: 10.1016/j.actbio.2026.06.005. https://doi.org/10.1016/j.actbio.2026.06.005
  10. Rossin R., Läppchen T., van den Bosch S. M., Laforest R., Robillard M. S. (2013). Diels-Alder reaction for tumor pretargeting: in vivo chemistry can boost tumor radiation dose compared with directly labeled antibody. Journal of Nuclear Medicine 54(11):1989-1995. DOI: 10.2967/jnumed.113.123745. https://doi.org/10.2967/jnumed.113.123745